- Home
- DWTX vs AYTU Comparison
DWTX vs AYTU Comparison
Compare DWTX & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DWTX
- AYTU
- Stock Information
- Founded
- DWTX 2012
- AYTU N/A
- Country
- DWTX United States
- AYTU United States
- Employees
- DWTX N/A
- AYTU N/A
- Industry
- DWTX
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- DWTX
- AYTU Health Care
- Exchange
- DWTX NYSE
- AYTU Nasdaq
- Market Cap
- DWTX 9.2M
- AYTU 9.6M
- IPO Year
- DWTX N/A
- AYTU N/A
- Fundamental
- Price
- DWTX $4.79
- AYTU $2.35
- Analyst Decision
- DWTX Strong Buy
- AYTU Strong Buy
- Analyst Count
- DWTX 1
- AYTU 2
- Target Price
- DWTX $10.00
- AYTU $10.00
- AVG Volume (30 Days)
- DWTX 27.2K
- AYTU 200.9K
- Earning Date
- DWTX 08-14-2025
- AYTU 05-14-2025
- Dividend Yield
- DWTX N/A
- AYTU N/A
- EPS Growth
- DWTX N/A
- AYTU N/A
- EPS
- DWTX N/A
- AYTU N/A
- Revenue
- DWTX N/A
- AYTU $81,659,000.00
- Revenue This Year
- DWTX N/A
- AYTU N/A
- Revenue Next Year
- DWTX N/A
- AYTU $8.68
- P/E Ratio
- DWTX N/A
- AYTU N/A
- Revenue Growth
- DWTX N/A
- AYTU 0.41
- 52 Week Low
- DWTX $1.62
- AYTU $0.95
- 52 Week High
- DWTX $29.28
- AYTU $2.87
- Technical
- Relative Strength Index (RSI)
- DWTX N/A
- AYTU 63.62
- Support Level
- DWTX N/A
- AYTU $2.10
- Resistance Level
- DWTX N/A
- AYTU $2.42
- Average True Range (ATR)
- DWTX 0.00
- AYTU 0.14
- MACD
- DWTX 0.00
- AYTU -0.01
- Stochastic Oscillator
- DWTX 0.00
- AYTU 77.78
About DWTX DOGWOOD THERAPEUTICS INC
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.